financial results

The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.

Excluding the sale of the company's colorectal cancer patents to Exact Sciences, its 2017 revenues rose 13 percent.

The company said that an increase in clinical genetic testing volume contributed to overall revenue growth.

The firm cited "strong demand for pathology products and companion diagnostics services" for revenue gains in its Diagnostics and Genomics Group.

Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.

Invitae reported $25.4 million in fourth quarter revenues compared to $9.2 million in Q4 2016, beating the consensus Wall Street estimate.

During the quarter, the company reopened its CLIA lab in New Haven, Connecticut, following the company's merger with Transgenomic in June.

The company also estimated full-year 2017 revenues to be between $23.7 million and $24.0 million, and announced a $15.8 million contract in Ethiopia.

Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.

The company's HIV testing revenues were up 24 percent year over year, while HCV testing revenues plummeted 68 percent.

Pages